Klaus-Michael Debatin

11PUBLICATIONS
131CO-AUTHORS
Molecular targetsAdolescent healthTumour immunologyHaematological tumoursCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (11)

|Apr 15, 2025
Remission induction in refractory, drug resistant pediatric PICALM::MLLT10+ B-cell acute lymphoblastic leukemia by venetoclax.

Alexandra Niedermayer, Jana Stursberg, Anke Katharina Bergmann

|Oct 05, 2024
The dual BCL-2 and BCL-XL inhibitor AZD4320 acts on-target and synergizes with MCL-1 inhibition in B-cell precursor ALL.

Maren Christiane Wichert, Colin Fortner, Alexandra Niedermayer

|Nov 14, 2023
A partial human LCK defect causes a T cell immunodeficiency with intestinal inflammation.

Victor G Lui, Manfred Hoenig, Berenice Cabrera-Martinez

|Jan 21, 2022
Bcl-XL but Not Bcl-2 Is a Potential Target in Medulloblastoma Therapy.

Mike-Andrew Westhoff, Marie Schuler-Ortoli, Daniela Zerrinius

|Oct 18, 2021
Evaluation of vecabrutinib as a model for noncovalent BTK/ITK inhibition for treatment of chronic lymphocytic leukemia.

Billy Michael Chelliah Jebaraj, Annika Müller, Rashmi Priyadharshini Dheenadayalan

Pageof 2